Sign In / Register
Recombinant Human CTLA-4 Fc Chimera His-tag Protein, CF
Catalog # 325-CT/CF | R&D Systems, Inc. a Bio-Techne Brand
Key Product Details
Accession #
Source
Sf 21 (baculovirus)
Structure / Form
Disulfide-linked homodimer
Conjugate
Unconjugated
Applications
Bioactivity
Product Specifications
Source
Spodoptera frugiperda, Sf 21 (baculovirus)-derived human CTLA-4 protein
| Human CTLA-4 (Ala37-Phe162) Accession # Q6GR94 |
IEGRMD | Human IgG1 (Pro100-Lys330) |
6-His tag |
| N-terminus | C-terminus | ||
Purity
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
N-terminal Sequence Analysis
Ala37
Predicted Molecular Mass
40 kDa (monomer)
Activity
Measured by its ability to inhibit IL-2 secretion by stimulated Jurkat human acute T cell leukemia cells. Linsley, P.S. et al. (1991) J. Exp. Med. 174:561.
The ED50 for this effect is 0.1-0.4 µg/mL when stimulated with 1 µg/mL Recombinant Human B7‑1/CD80 Fc Chimera (Catalog #
140-B1) in the presence of PHA.
The ED50 for this effect is 0.1-0.4 µg/mL when stimulated with 1 µg/mL Recombinant Human B7‑1/CD80 Fc Chimera (Catalog #
140-B1) in the presence of PHA.
Scientific Data Images for Recombinant Human CTLA-4 Fc Chimera His-tag Protein, CF
Recombinant Human CTLA-4 Fc Chimera His-tag Protein Bioactivity
Recombinant Human CTLA-4 Fc Chimera (Catalog # 325-CT/CF) inhibits IL-2 secretion by stimulated Jurkat human acute T cell leukemia cells. The ED50 for this effect is 0.1-0.4 µg/mL when stimulated with 1 µg/mL Recombinant Human B7-1 Fc Chimera (Catalog # 140-B1) in the presence of PHA.
Recombinant Human CTLA-4 Fc Chimera His-tag Protein SDS-PAGE
1 μg/lane of Recombinant Human CTLA-4 Fc Chimera was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by silver staining, showing single bands at 51 kDa and 94 kDa, respectively .Formulation, Preparation and Storage
325-CT/CF
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
| Reconstitution | Reconstitute at 200 μg/mL in sterile PBS. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: CTLA-4
CTLA-4 (cytotoxic T-lymphocyte-4, designated CD152), is a type I transmembrane T cell inhibitory molecule that is a member of the Ig superfamily (1, 2). Human or mouse CTLA-4 cDNA encodes 223 amino acids (aa) including a 35 aa signal sequence, a 126 aa extracellular domain (ECD) with one Ig-like V-type domain, a 21 aa transmembrane (TM) sequence, and a 41 aa cytoplasmic sequence. It is found as a covalent homodimer of 41‑43 kDa (2). Within the ECD, human CTLA-4 shares 68%, 71% and 83‑86% aa sequence identity with mouse, rat and porcine/bovine/rabbit/feline/canine CTLA-4, respectively. A 174 aa form that lacks TM and cytoplasmic sequences (sCTLA-4) is possibly secreted (3‑5). Isoforms of 56‑79 aa that mainly contain parts of the cytoplasmic domain are reported. In mouse, an isoform lacking the Ig-like domain has ligand-independent inhibitory activity and is termed liCTLA-4 (6). CD28, which is structurally related to CTLA-4, is constitutively expressed on naïve T cells and promotes T cell activation when engaged by B7-2 on antigen-presenting cells (APC) within the immunological synapse (IS) (1, 7, 8). In contrast, CTLA-4 is recruited from intracellular vesicles to the IS beginning 1, 2 days after T cell activation (2, 7, 8). It forms a linear lattice with B7‑1 on APC, inducing negative regulatory signals and ending T cell activation (9). Abatacept, a therapeutic human CTLA-4-Ig fusion protein (trade name Orencia), competes with CD28 for B7-1 and B7-2 binding and has been used to antagonize T cell activation in autoimmune conditions and to enhance transplant survival (10). Mice deleted for CTLA-4 show no abnormalities until after birth, but then develop lethal autoimmune reactions due to continued T cell activation and poor control by regulatory T cells, which constitutively express CTLA-4 in wild-type mice and humans (11‑13).
References
- Harper, K. et al. (1991) J. Immunol. 147:1037.
- Teft, W.A. et al. (2006) Annu. Rev. Immunol. 24:65.
- Magistrelli, G. et al. (1999) Eur. J. Immunol. 29:3596.
- Tector, M. et al. (2009) BMC Immunol. 10:51.
- Oaks, M.K. and K.M. Hallett (2000) J. Immunol. 164:5015.
- Vijayakrishnan, L. et al. (2004) Immunity 20:563.
- Pentcheva-Hoang, T. et al. (2004) Immunity 21:401.
- Jansson, A. et al. (2005) J. Immunol 175:1575.
- Darlington, P.J. et al. (2005) J. Immunol. 175:996.
- Platt, A.M. et al. (2010) J. Immunol. 185:1558.
- Wing, K. et al. (2008) Science 322:271.
- Friedline, R.H. et al. (2009) J. Exp. Med. 206:421.
- Jain, N. et al. (2010) Proc. Natl. Acad. Sci. USA 107:1524.
Long Name
Cytotoxic T-lymphocyte-associated Molecule 4
Alternate Names
CD152, CTLA4
Gene Symbol
CTLA4
UniProt
Product Documents for Recombinant Human CTLA-4 Fc Chimera His-tag Protein, CF
Product Specific Notices for Recombinant Human CTLA-4 Fc Chimera His-tag Protein, CF
For research use only
Citations for Recombinant Human CTLA-4 Fc Chimera His-tag Protein, CF (7)
Showing
1
-
7 of
7 publications
Showing All
Filter By:
Search Title:
Citations are publications that use Bio-Techne products. Selected citations for Recombinant Human CTLA-4 Fc Chimera His-tag Protein, CF include:
-
Species: Human
Sample Types: Whole Cells
Applications: BioassayBD Hock et al. (2017-03-03), Idelalisib and caffeine reduce suppression of T cell responses mediated by activated chronic lymphocytic leukemia cells PLoS ONE, 2017-012(3):e0172858.
PMID: 28257435 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayKowalczyk A et al. (2014-01-22), Cell-extrinsic CTLA4-mediated regulation of dendritic cell maturation depends on STAT3. Eur J Immunol, 2014-044(4):1143-55.
PMID: 24338929 -
Species: Human
Sample Types: Whole Cells
Applications: BioassaySteidl C et al. (2011-03-02), MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature, 2011-0471(7338):377-81.
PMID: 21368758 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayManiar A et al. (2010-06-02), Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood, 2010-0116(10):1726-33.
PMID: 20519625 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayShan M et al. (2009-10-28), Lung myeloid dendritic cells coordinately induce TH1 and TH17 responses in human emphysema. Sci Transl Med, 2009-11(4):4ra10.
PMID: 20368170 -
Sample Types: N/A
Applications: ELISA (Standard)Sakthivel P et al. (2007-04-01), The soluble forms of CD28, CD86 and CTLA-4 constitute possible immunological markers in patients with abdominal aortic aneurysm. J. Intern. Med., 2007-0261(4):399-407.
PMID: 17391115 -
Species: Human
Sample Types: Whole Cells
Applications: Flow CytometryLazetic S et al. (2002-08-06), Chimeric co-stimulatory molecules that selectively act through CD28 or CTLA-4 on human T cells. J. Biol. Chem., 2002-0277(41):38660-8.
PMID: 12167647
There are no citations that match your criteria.
Loading...
